Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shugan Jieyu Capsule in Generalized Anxiety Disorder
NCT05772104Phase 3Recruiting
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Feb 2025
- Modality
- HM (Herbal Medicine)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Shugan Jieyu Capsules with Shugan Jieyu Capsules Placebo (2 arms). Primary endpoint: Hamilton Anxiety Rating Scale at 12 weeks. Started Apr 2023; status: recruiting.
02
Drugs
Shugan Jieyu
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT05772104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05772104.